Pear Therapeutics Reports First Quarter 2022 Financial Results
- BOSTON--(BUSINESS WIRE)--Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today reported financial results for its first quarter ended March 31, 2022. “Our momentum in 2021 continued into 2022 with strong revenue and prescription volume growth in the first quarter,” said Corey McCann, M.D., Ph.D., President and Chief Executive Officer of Pear Therapeutics. “We continue to expand the reach of our products with advances such as the availability of reSET® and reSET-O® in Spanish, expansion into new states like Oklahoma and Michigan, and recognition from CMS via a HCPCS code establishing an important reimbursement milestone for PDTs. We also continue to advance our payor value proposition with 12-month and 24-month health economic data demonstrating durability of clinical outcomes and long-term reduction in healthcare resource utilization.” First Quarter 2022 Financial and Operational Performance Metrics Results First quarter revenue grew to $2.7 million, up from $1.3 million in Q4 2021, and compared with $376 thousand for the first quarter of 2021. Net Revenue and Key Operating Metrics Q1 2022 Actual Full Year 2022 Guidance Net Revenue $2.7 million $22.0 million Total Prescriptions1 >9,200 50,000-60,000 Fulfillment Rate2 57% 50-65% Payment Rate3 50% 50-65% Average Selling Price (ASP)4 $1,353 $1,150-$1,350 First Quarter 2022 Business and Strategic Highlights Prescribing We saw growing demand with more than 9,200 total prescriptions for our three commercial products in the first quarter. Coverage We expanded access to reSET and reSET-O through a value-based access agreement with Oklahoma Medicaid and an access agreement with the state of Michigan. The Centers for Medicare & Medicaid Services (CMS) established a new Level II Healthcare Common Procedure Coding System (HCPCS) code to describe Prescription Digital Behavioral Therapy, FDA Cleared, per Course of Treatment including PDTs such as Pear’s reSET, reSET-O, and Somryst®, which became effective on April 1, 2022. Bipartisan, bicameral lead sponsors introduced federal legislation, the Access to Prescription Digital Therapeutics Act of 2022, which, if enacted, will create a benefit category for PDTs. Real World Evidence We presented interim data at the World Sleep Conference from DREAM, a fully virtual, decentralized study of Somryst utilizing the PearCreate™ clinical trial infrastructure, which showed treatment with Somryst achieved significant and meaningful reductions in insomnia severity through six months.5 Health Equity and Inclusion We launched Spanish-language availability of reSET and reSET-O to address health equity and health care disparities and expand access for those in the Hispanic American community living with substance use disorder (SUD) and opioid use disorder (OUD). PearCreate and PearConnect™ We executed a services agreement with SoftBank Corp. to develop a digital therapeutic for the treatment of sleep/wake disorders for the Japanese market as part of Pear’s strategy to commercialize digital therapeutics in international markets. We made our PearConnect platform available to healthcare providers in the Epic App Orchard Gallery. Initially, this will allow healthcare providers who implement the application the ability to access the PearConnect platform within Epic’s leading EHR platform to remotely monitor patients who have been prescribed reSET and reSET-O. Subsequent Events in Second Quarter 2022 Prescribing We announced a program to offer patients seeking treatment for SUD or OUD access to select telehealth providers through our “find a provider” tool, along with in-person care options. Pear’s first telehealth offering included in this program is with PursueCare, a leading telehealth addiction treatment provider with a digital health model for SUD and OUD treatment. We announced QuickMD, a telemedicine platform providing consultations and urgent care over phone and video, as the second telehealth provider available via our “find a provider” tool. PearCreate and PearConnect We received Safer Technologies Program (STeP) designation from the FDA for our product candidate Pear-010 for the treatment of acute and chronic pain. Real World Evidence We will present 12-month health economic data for reSET-O at The Professional Society for Health Economics and Outcomes Research annual conference (ISPOR 2022) on May 16 at 5:30 p.m. ET, demonstrating a durable treatment effect, among other important findings, in more than 900 patients with OUD after initiation of reSET-O. The full results of the study have been accepted for publication in a peer-reviewed journal in the second quarter. We will present 24-month health economic data for Somryst at ISPOR 2022 on May 17 at 12:15 p.m. ET, demonstrating clinically meaningful improvements in insomnia symptoms as well as reductions in the use of health care services through 24-months. The full results of the study have been accepted for publication in a peer-reviewed journal in the second quarter. Internet Posting of Information Pear routinely posts information that may be important to investors in the “Investors” section of its website at www.peartherapeutics.com. The company encourages investors and potential investors to consult its website regularly for important information about the company, including its investor presentation. Conference Call and Webcast Information Pear management team will host a conference call and live webcast today, May 16, 2022, at 4:30 p.m. ET. To access the live conference call via telephone, please dial [(877) 814-6630 (US callers) or (409) 216-0625 (international callers) and provide passcode 6975673. A live webcast will be available in the Investors section of the company’s website at www.peartherapeutics.com. A replay of the audio webcast will be available in the Investors section of the company's website at www.peartherapeutics.com approximately two hours after completion of the call and will be archived for up to 30 days. For additional information about reported results, investors will be able to access Pear’s Form 10-Q on the company’s website at www.peartherapeutics.com or on the Securities and Exchange Commission website, www.sec.gov. The conference call may include forward-looking statements. See the cautionary information about forward-looking statements in the Forward-Looking Statements section of this press release. About Pear Therapeutics Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the federal securities laws that are subject to risks and uncertainties and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements generally relate to future events involving, or future performance of, Pear. For example, Pear’s operating and financial guidance for full year 2022, whether Pear will advance its payor value proposition with 12-month and 24-month health economic data, whether Pear will develop a digital therapeutic for sleep/wake disorders for the Japanese market or develop digital therapeutics for other international markets, whether the Spanish-language availability of reSET and reSET-O will address health equity and health care disparities and expand access for those in the Hispanic American community living with SUD and OUD, and statements regarding its ability to advance its product candidates are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “guidance”, “may”, “should”, “could”, “might”, “plan”, “possible”, “project”, “strive”, “aim”, “budget”, “forecast”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential”, “target”, or “continue”, or the negatives of these terms or variations of them or similar terminology. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Pear and its management are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) Pear’s ability to meet its full year 2022 revenue forecast or other 2022 guidance, (ii) Pear’s ability to advance the development, clinical testing or regulatory pathway of its AUD or depression assets; (iii) Pear’s ability to successfully commercialize its PDTs; (iv) changes in applicable laws or regulations; (v) the possibility that Pear may be adversely affected by other economic, business, regulatory, and/or competitive factors; (vi) Pear’s estimates of expenses and profitability; (vii) the evolution of the markets in which Pear competes; (viii) the ability of Pear to implement its strategic initiatives and continue to develop its existing products; (ix) the ability of Pear to defend its intellectual property and satisfy regulatory requirements; (x) the ability of Pear to issue equity or equity-linked securities in the future or otherwise raise capital to fund its operations; (xi) the impact of the COVID-19 pandemic on Pear’s business; and (xii) other risks and uncertainties set forth in Pear’s filings with the SEC (including those described in the Risk Factors section). These filings will identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, which are based only on information currently available to us and speak only as of the date of this release. Pear assumes no obligation to publicly update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. Pear gives no assurance that Pear will achieve its expectations. ___________________________________ References: 1 Total Prescriptions in a given period is (a) the imputed number of prescriptions based on revenue recognized under access agreements plus (b) the number of prescriptions written which are not imputed under access agreements. 2 Fulfillment Rate in a given period is (a) the number of prescriptions for which either a patient commences therapy or there is a contractual payment obligation and revenue has been recognized divided by (b) Total Prescriptions. (Total Prescriptions times Fulfillment Rate equals Fulfilled Prescriptions.) 3 Payment Rate in a given period is (a) the number of prescriptions for which the company receives payment divided by (b) Fulfilled Prescriptions. (Fulfilled Prescriptions times Payment Rate equals Paid Prescriptions.) 4 Average Selling Price, or ASP, in a given period is the average price received by the Company per script for which the Company receives payment. 5 Morin, C. Early data from a prescription digital therapeutic delivering CBT for insomnia. World Sleep Congress 2022. Pear Therapeutics, Inc. Unaudited Condensed Consolidated Statements of Operations Three Months Ended March 31, (in thousands, except per share data) 2022 2021 Revenue Product revenue $ 2,749 $ 300 Collaboration and license revenue — 76 Total revenue 2,749 376 Cost and operating expenses Cost of product revenue 1,481 738 Research and development 13,264 7,490 Selling, general and administrative 22,745 13,299 Total cost and operating expenses 37,490 21,527 Loss from operations (34,741 ) (21,151 ) Other income (expenses): Interest and other (expense) income, net (1,016 ) (1,026 ) Change in estimated fair value of earn-out liabilities 14,627 — Change in estimated fair value of warrant liabilities (2,729 ) (163 ) Loss on issuance of legacy convertible preferred stock — (2,053 ) Total other income (expense) 10,882 (3,242 ) Net (loss) income $ (23,859 ) $ (24,393 ) Net (loss) earnings per share: Basic and diluted $ (0.17 ) $ (0.22 ) Weighted average common shares outstanding: Basic and diluted 137,852 108,658 Pear Therapeutics, Inc. Unaudited Condensed Consolidated Balance Sheets (in thousands) March 31, 2022 December 31, 2021 Assets Current assets: Cash and cash equivalents $ 89,434 $ 169,567 Short-term investments 47,967 5,004 Accounts receivable 4,131 1,794 Prepaid expenses and other current assets 8,519 8,876 Total current assets 150,051 185,241 Property and equipment, net 6,386 6,255 Right-of-use assets 10,196 — Restricted cash 411 411 Other long-term assets 5,048 5,253 Total assets $ 172,092 $ 197,160 Liabilities and stockholders’ deficit Current liabilities: Accounts payable $ 3,750 $ 1,806 Accrued expenses and other current liabilities 12,679 17,946 Lease liabilities - current 1,760 — Deferred revenues 1,020 421 Debt 27,170 26,993 Total current liabilities 46,379 47,166 Lease liabilities - noncurrent 9,695 — Embedded debt derivative 675 675 Warrant liabilities 11,257 8,528 Earn-out liability 33,736 48,363 Other long-term liabilities 841 1,994 Total liabilities 102,583 106,726 Commitments and contingencies Stockholders’ equity: Common stock 14 14 Additional paid-in capital 341,380 338,404 Accumulated deficit (271,842 ) (247,983 ) Accumulated other comprehensive income (43 ) (1 ) Total stockholders’ equity 69,509 90,434 Total liabilities and stockholders’ equity $ 172,092 $ 197,160
- 05/16/2022
|
Pear Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
- BOSTON--(BUSINESS WIRE)--Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today reported financial results for its fourth quarter and full year 2021 ended December 31, 2021. Fourth Quarter 2021 Financial Results Pear’s total revenue for the fourth quarter of 2021 was $1.3 million, compared with $34 thousand for the fourth quarter of 2020, with the increase over the prior year period primarily related to product sales of its three FDA-authorized products. Full Year 2021 Financial and Operational Performance Metrics Results In 2021, Pear achieved strong financial results and commercial progress from its portfolio of marketed products across key performance metrics of prescriptions, fulfillment, covered lives, and revenue. Full Year 2021 Financial and Key Operating Performance Metrics* (Guidance) (Actual) Revenue $4M $4.2M Prescriptions 12,500 14,000+ Fulfillment Rate 50% ~51% Covered Lives 30M-40M 31.7M+ Gross to Net 8% 18% * To illustrate how prescriptions written, fulfillment rate, and covered lives relate to product revenue, we believe it is helpful to provide a hypothetical scenario of 100 prescriptions written with a 50% fulfillment rate and a 50% payment rate. We use covered lives as a metric that is expected to impact payment rate because, as we grow the number of covered lives for our three products, the payment rate should increase. In this hypothetical scenario, Pear has 50 filled prescriptions, of which 25 are paid. Product revenue for the 100 prescriptions written is calculated by multiplying (a) 25 paid prescriptions by (b) the wholesale acquisition cost (WAC) for the respective prescriptions, reduced by (c) any applicable discounts and rebates as well as estimated contingency management costs, if applicable. “We showed strong execution in 2021, with the company reaching its first commercial inflection point, highlighted by our rapid progress on provider adoption and payor access for our three commercial PDTs,” said Corey McCann, M.D., Ph.D., President and Chief Executive Officer of Pear Therapeutics. “In 2022, we will build value for our shareholders by continuing to bring our PDTs to more and more patients and providers, increase access to our PDTs to help improve the lives of the patients we serve, publish health economic data generated in the real world, advance our pipeline, develop our commercial platform called PearConnect™ and our development platform called PearCreate™.” 2021 Business Highlights Prescribing More than 550 prescribers wrote prescriptions for reSET, reSET-O, and Somryst in 2021. Providers deploying Pear’s PDTs include large addiction health systems, hospital network providers, and academic medical centers such as ChristianaCare, Crossroads, Northwell Health, M Health Fairview, and Kaiser Permanente Washington. The American Medical Association (AMA) Current Procedural Terminology (CPT) Editorial Panel announced CPT Category 1 codes for Remote Therapeutic Monitoring (RTM) Services and the Remote Therapeutic Monitoring Treatment Management Services (RTM-TMS) guidelines to clarify coding of cognitive behavioral therapy (CBT) monitoring services, which are expected to go into effect January 2023. Coverage At year-end, more than 30 organizations provided access to Pear’s PDTs for the treatment of substance use disorder (SUD), opioid use disorder (OUD), and chronic insomnia by either listing on a formulary as a covered benefit or purchasing products in bulk. Pear’s PDTs were made available on major national product formularies, including two of the top six pharmacy benefit managers (PBMs). Massachusetts became the first state to cover PDTs for all Medicaid patients. Pear’s products, reSET and reSET-O, were added to MassHealth’s Non-Drug Product List, effective November 1, 2021. Real World Evidence Pear announced the publication of an analysis of real-world data demonstrating patients (n=64) with OUD who used an 84-day prescription of reSET-O compared to patients who did not engage with reSET-O resulted in net cost savings in hospital facility and clinician services over the 9-month period of $2,708, which was largely driven by a 46% lower incidence of hospital-related stays, as measured from the patient’s use of, or non-engagement with, reSET-O.1 Health Equity and Inclusion Pear demonstrated its commitment to underserved populations by working with groups including the Ninilchik Village Tribe in Alaska and State Opioid Response (SOR) grants by Indiana, Kentucky, and Ohio. Pipeline Pear received Breakthrough Device Designation from the FDA for its PDT product candidate designed for the treatment of alcohol use disorder (AUD) to potentially expand its addiction franchise, which includes FDA-authorized products to treat SUD and OUD. Dual Platform: PearCreate™ and PearConnect™ Pear continued to aggregate digital therapeutics and digital biomarkers in the service of creating the industry’s first comprehensive PDT platform. In 2021, Pear acquired and/or licensed two digital therapeutic assets designed to treat patients with a range of depression symptoms to support its development of a PDT candidate that may be for use alone or in combination with pharmacotherapy. Pear also executed a portfolio of in-licensing deals involving digital biomarkers assessing voice and keystroke, along with wearables and ingestible sensor technologies. Subsequent Events in Q1 2022 Prescribing On February 16, 2022, the Centers for Medicare & Medicaid Services (CMS) established a new Level II Healthcare Common Procedure Coding System (HCPCS) code to describe Prescription Digital Behavioral Therapy, FDA Cleared, per Course of Treatment including PDTs such as Pear’s reSET, reSET-O, and Somryst, which is scheduled to become effective on April 1, 2022. Coverage Pear expanded access to its PDTs reSET and reSET-O through a value-based agreement with Oklahoma Health Care Authority (Oklahoma Medicaid), an agreement with Point32Health, founded by Tufts Health Plan and Harvard Pilgrim Health Care, and funding provided by the state of Michigan. On March 10, 2022, bipartisan, bicameral federal legislation, the Access to Prescription Digital Therapeutics Act of 2022, was introduced and, if enacted, will expand Medicare coverage to include PDTs. Real World Evidence On March 15, 2022 at World Sleep, interim data from DREAM, a fully virtual, decentralized study of Somryst utilizing the PearCreate clinical trial infrastructure, found treatment with Somrystachieved significant and meaningful reductions in insomnia severity through six months.2 Health Equity and Inclusion In February 2022, announced availability of reSET and reSET-O in Spanish to address health equity and health care disparities and expand access for those in the Hispanic American community living with SUD and OUD. Dual Platform: PearCreate and PearConnect On March 21, 2022, announced a development agreement with SoftBank Corp. to develop a Japanese-language digital therapeutic for the treatment of sleep/wake disorders for the Japanese market as part of Pear’s strategy to commercialize digital therapeutics in international markets. On March 24, 2022, Pear announced its PearConnect platform is available to healthcare providers in the Epic App Orchard Gallery. Initially, this will allow healthcare providers who implement the application the ability to access the PearConnect platform within Epic’s leading electronic health record (EHR) platform to remotely monitor patients who have been prescribed reSET and reSET-O. 2022 Financial and Operational Outlook Pear provides guidance for full year 2022 as follows: Key Performance Operating Metrics Guidance Revenue $22M Prescriptions 50,000-60,000 Fulfillment Rate 50-65% Covered Lives 100M-120M Internet Posting of Information Pear routinely posts information that may be important to investors in the “Investors” section of its website at www.peartherapeutics.com. The company encourages investors and potential investors to consult its website regularly for important information about the company, including its investor presentation. Conference Call and Webcast Information Pear management team will host a conference call and live webcast on March 28, 2022 at 4:30 p.m. ET. To access the live conference call via telephone, please dial (877) 814-6630 (US callers) or (409) 216-0625 (international callers) and provide passcode 8586341. A live webcast will be available in the Investors section of the company’s website at www.peartherapeutics.com. A replay of the audio webcast will be available in the Investors section of the company's website at www.peartherapeutics.com approximately two hours after completion of the call and will be archived for up to 30 days. Pear plans to file its Form 10-K for the year ended December 31, 2021, with the Securities and Exchange Commission on or before March 31, 2022. For additional information about reported results, investors will be able to access the Form 10-K on the company’s website at www.peartherapeutics.com or on the SEC site, www.sec.gov. The conference call may include forward-looking statements. See the cautionary information about forward-looking statements in the Forward-Looking Statements section of this press release. About Pear Therapeutics Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the federal securities laws that are subject to risks and uncertainties and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. Forward looking statements generally relate to future events involving, or future performance of, Pear. For example, Pear’s operating and financial guidance for full year 2022, whether its PDT product candidate for alcohol use disorder will be authorized by FDA and statements regarding its ability to advance its product candidates are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “guidance”, “may”, “should”, “could”, “might”, “plan”, “possible”, “project”, “strive”, “aim”, “budget”, “forecast”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential”, “target”, or “continue”, or the negatives of these terms or variations of them or similar terminology. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Pear and its management are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) Pear’s ability to meet its full year 2022 revenue forecast or other 2022 guidance, (ii) Pear’s ability to advance the development, clinical testing or regulatory pathway of its AUD or depression assets; (iii) Pear’s ability to successfully commercialize its PDTs; (iv) changes in applicable laws or regulations; (v) the possibility that Pear may be adversely affected by other economic, business, regulatory, and/or competitive factors; (vi) Pear’s estimates of expenses and profitability; (vii) the evolution of the markets in which Pear competes; (viii) the ability of Pear to implement its strategic initiatives and continue to innovate its existing products; (ix) the ability of Pear to defend its intellectual property and satisfy regulatory requirements; (x) the ability of Pear to issue equity or equity-linked securities in the future or otherwise raise capital to fund its operations; (xi) the impact of the COVID-19 pandemic on Pear’s business; and (xii) other risks and uncertainties set forth in Pear’s filings with the SEC (including those described in the Risk Factors section). These filings will identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, which are based only on information currently available to us and speak only as of the date of this release. Pear assumes no obligation to publicly update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. Pear gives no assurance that Pear will achieve its expectations. References: 1. Velez FF, Colman S, Kauffman L, Ruetsch C, Anastassopoulos K, Maricich YA. Comparison of Healthcare Resource Utilization Between Patients Who Engaged or Did Not Engage With a Prescription Digital Therapeutic for Opioid Use Disorder. Clinicoecon Outcomes Res. 2021;13:909-916 https://doi.org/10.2147/CEOR.S334274 2. Morin, C. Early data from a prescription digital therapeutic delivering CBT for insomnia. World Sleep Congress 2022. Pear Therapeutics, Inc. Condensed Consolidated Statements of Operations Three Months Ended December 31, Year Ended December 31, (in thousands, except per share data) 2021 2020 2021 2020 Revenue Product revenue $ 1,198 $ 34 $ 3,748 $ 149 Collaboration and license revenue 122 — 460 9,235 Total revenue 1,320 34 4,208 9,384 Cost and operating expenses Cost of product revenue 1,648 377 5,233 1,718 Research and development 12,098 6,318 37,041 28,084 Selling, general and administrative 21,808 22,581 67,619 56,226 Total cost and operating expenses 35,554 29,276 109,893 86,028 Loss from operations (34,234) (29,242) (105,685) (76,644) Other income (expenses): Interest and other (expense) income, net (1,058) (841) (4,144) (1,767) Change in estimated fair value of earn-out liabilities 47,038 — 47,038 — Change in estimated fair value of warrant liabilities 7,004 (747) (298) (795) Loss on extinguishment of debt — — — (998) Loss on issuance of legacy convertible preferred stock — (16,819) (2,053) (16,819) Total other income (expense) 52,984 (18,406) 40,543 (20,379) Net (loss) income $ 18,750 $ (47,648) $ (65,142) $ (97,023) Unrealized (loss) gain on short-term investments $ (1) $ (4) $ (1) $ (29) Comprehensive (loss) income $ 18,749 $ (47,652) $ (65,143) $ (97,052) Loss on repurchase of convertible preferred stock — (11,053) — (11,053) Net (loss) income attributable to common stockholders $ 18,750 $ (58,676) $ (65,142) $ (108,076) Net (loss) earnings per share: Basic $ 0.16 $ (0.63) $ (0.57) $ (1.21) Diluted $ 0.13 $ (0.63) $ (0.57) $ (1.21) Weighted average common shares outstanding: Basic 120,356 93,119 113,328 89,216 Diluted 146,796 93,119 113,328 89,216 Pear Therapeutics, Inc. Condensed Consolidated Balance Sheets December 31, (in thousands) 2021 2020 Assets Current assets: Cash and cash equivalents $ 169,567 $ 110,900 Short-term investments 5,004 13,535 Accounts receivable 1,794 257 Prepaid expenses and other current assets 8,876 1,365 Total current assets 185,241 126,057 Property and equipment, net 6,255 4,277 Restricted cash 411 1,161 Other long-term assets 5,253 871 Total assets $ 197,160 $ 132,366 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 1,806 $ 4,506 Accrued expenses and other current liabilities 17,946 9,568 Deferred revenues 421 267 Debt 26,993 26,345 Total current liabilities 47,166 40,686 Embedded debt derivative 675 675 Warrant liabilities 8,528 2,650 Earn-out liabilities 48,363 — Other long-term liabilities 1,994 1,239 Total liabilities 106,726 45,250 Commitments and contingencies Legacy convertible preferred stock — — Stockholders’ equity: Common Stock 14 11 Additional paid-in capital 338,404 269,946 Accumulated deficit (247,983) (182,841) Accumulated other comprehensive (loss) income (1) — Total stockholders’ equity 90,434 87,116 Total liabilities and stockholders’ equity $ 197,160 $ 132,366
- 03/28/2022
|
